Information letter-appeal to healthcare professionals regarding the safety of use of the medicinal products LEVOFLOXACIN and LEFSAN. Systemic antibacterial agents of the fluoroquinolone group, risk of long-term serious adverse reactions, reminder of restrictions on use

01.10.2026 60 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо безпеки застосування лікарських засобів ЛЕВОФЛОКСАЦИН та ЛЕФСАНPDF · 135 КБ

Завантажити

Information letter-appeal to healthcare professionals regarding the safety of use of the medicinal products LEVOFLOXACIN and LEFSAN. Systemic antibacterial agents of the fluoroquinolone group, risk of long-term serious adverse reactions, reminder of restrictions on use

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter-appeal to healthcare professionals regarding the safety of use of the medicinal products LEVOFLOXACIN and LEFSAN. Systemic antibacterial agents of the fluoroquinolone group, risk of long-term serious adverse reactions, reminder of restrictions on use

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration